ETFs positioned on Shanghai Henlius Biotech, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.04% 2 M€ -.--%
0.01% 7 M€ -.--% -
Logo Shanghai Henlius Biotech, Inc.
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Employees
3,637
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
20.92CNY
Average target price
18.79CNY
Spread / Average Target
-10.20%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. ETFs Shanghai Henlius Biotech, Inc.